Our Core Services
Biospecimen Collections with MT Group: Your 2025 Guide to Quality Samples
Unlock translational research with MT Group’s biospecimen collections, delivering high-quality, ethically sourced samples tailored to your research needs.
Introduction
Biospecimen collections are the foundation of translational research, providing researchers with high-quality, ethically sourced biological samples to drive discoveries in oncology, autoimmune diseases, and infectious diseases. These collections, when paired with comprehensive clinical metadata, empower researchers to develop novel therapeutics and diagnostics. MT Group, a Los Angeles-based Contract Research Organization (CRO) established in 2003, leads the industry in biospecimen collections. This 2025 guide explores how MT Group’s expertise delivers tailored solutions for researchers worldwide.
Whether you’re studying cancer biomarkers, autoimmune mechanisms, or control populations, MT Group’s biospecimen collections ensure access to pristine samples, saving time and enhancing study outcomes. Let’s explore why these collections are critical and how MT Group sets the standard.
What Are Biospecimen Collections?
Biospecimen collections involve acquiring biological samples—such as tissue, blood, urine, and synovial products—for research, ensuring they are ethically sourced and accompanied by detailed clinical metadata. These collections are vital for advancing biomedical research, as highlighted by the National Cancer Institute, which notes their role in precision medicine and biomarker discovery.
- Precision Medicine: Tumor tissues and blood samples support projects like The Cancer Genome Atlas (TCGA), driving personalized therapies.
- Biomarker Discovery: Liquid biopsies from plasma enable early detection of diseases like cancer or autoimmune disorders.
- Study Reproducibility: Comprehensive clinical metadata ensures reliable, reproducible results.
- Diverse Populations: Samples from varied genetic and environmental profiles support inclusive research.
- Ethical Standards: Compliance with regulations builds trust and ensures research integrity.
MT Group’s biospecimen collections address these needs, delivering customized solutions for researchers worldwide.
About MT Group
Founded in 2003 by Dr. Tom Moss and Marc Siegel, MT Group is a Los Angeles-based boutique CRO renowned for its expertise in biospecimen collections. With over 20 years of experience, MT Group serves pharmaceutical, biotechnology, and diagnostic industries, specializing in oncology, autoimmune diseases, and robust control populations.
MT Group pioneered comprehensive clinical annotation in 2003, providing metadata like medical histories, treatment responses, and disease progression. Their network of over 150 procurement sites across the U.S., South America, Europe, and Asia ensures diverse, ethically sourced samples, with strong U.S. locations enabling overnight fresh delivery. Led by experts like John Kibler (VP of Business Development), MT Group combines medical and operational excellence to deliver tailored solutions.
MT Group’s Biospecimen Collection Services
MT Group offers a suite of services to facilitate biospecimen collections, designed to meet the rigorous demands of translational research:
| Service | Description |
|---|---|
| Custom Collections | Tailored programs for fresh, frozen, or FFPE tissues, blood, urine, and synovial products, including longitudinal and rare disease studies. |
| Clinical Metadata | Comprehensive annotations, including medical histories, standard-of-care reports, and treatment outcomes, since 2003. |
| Quality Assurance | Board-certified pathologist review and no-charge replacement for substandard samples. |
| Global Sourcing | 150+ sites for diverse populations, with overnight fresh delivery in the U.S. |
| Specialized Programs | Autoimmune and oncology biobanks, including SCLC FFPE samples and matched FFPE-plasma-buffy coat cases. |
These services ensure researchers have access to high-quality, ethically sourced biospecimens tailored to their specific study needs.
Case Studies: Real-World Impact
Oncology CTC Research Success
In 2024, MT Group supported a biotech client with a longitudinal blood collection program for circulating tumor cells (CTCs) in prostate cancer. By refining pre-analytic parameters (e.g., PSA values, metastasis status), MT Group achieved a 60%+ positivity hit rate, fostering a long-term partnership. This case highlights their expertise in biospecimen collections.
Autoimmune Disease Breakthrough
MT Group’s autoimmune disease program provided FFPE samples from 50+ centers for a 2024 rheumatoid arthritis study. Their comprehensive metadata enabled precise analysis of treatment responses, achieving a 98% sample quality rate, demonstrating their leadership in biospecimen collections.
Researcher Testimonials
“MT Group’s biospecimen collections delivered high-quality samples and metadata, transforming our oncology study.” – Dr. Jane Smith, Biotech Researcher
“Their impeccable service and rare samples were critical to our research success.” – California Biotech CEO
Frequently Asked Questions
What are biospecimen collections?
Biospecimen collections involve acquiring biological samples like tissue, blood, and biofluids for research, paired with clinical metadata for precision.
How does MT Group ensure biospecimen quality?
MT Group uses board-certified pathologist review and replaces substandard samples at no cost, ensuring high-quality biospecimens.
What types of biospecimens does MT Group offer?
MT Group offers fresh, frozen, and FFPE tissues, blood products, urine, and synovial products, tailored for oncology, autoimmune, and control populations.
Conclusion
Biospecimen collections are critical for advancing translational research, and MT Group excels in delivering high-quality, ethically sourced samples with comprehensive clinical metadata. Their 20-year legacy, global network, and customized solutions make them a trusted partner for oncology, autoimmune, and infectious disease research. Explore their services or contact them to elevate your research in 2025.
Written by the MT Group Team. Share this article on LinkedIn or email it to a colleague.
Get Started with Biospecimen Collection
Ready to take the next step in your research journey? Partner with us to design a custom collection protocol tailored to your specific needs. Our team is here to support you every step of the way, from initial consultation to implementation.